Brian Skorney
Stock Analyst at Baird
(3.60)
# 802
Out of 5,239 analysts
122
Total ratings
48.86%
Success rate
7.17%
Average return
Main Sectors:
Stocks Rated by Brian Skorney
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MIRM Mirum Pharmaceuticals | Maintains: Outperform | $112 → $129 | $106.88 | +20.70% | 8 | May 7, 2026 | |
| ANRO Alto Neuroscience | Maintains: Outperform | $41 → $38 | $24.63 | +54.28% | 6 | Apr 2, 2026 | |
| XENE Xenon Pharmaceuticals | Maintains: Outperform | $63 → $97 | $55.00 | +76.36% | 2 | Mar 9, 2026 | |
| SRPT Sarepta Therapeutics | Maintains: Neutral | $21 → $15 | $19.13 | -21.59% | 13 | Nov 4, 2025 | |
| CRNX Crinetics Pharmaceuticals | Maintains: Outperform | $58 → $62 | $36.91 | +67.98% | 5 | Sep 26, 2025 | |
| BHVN Biohaven | Maintains: Outperform | $57 → $52 | $9.20 | +465.22% | 4 | Aug 12, 2025 | |
| NBIX Neurocrine Biosciences | Maintains: Outperform | $180 → $186 | $155.80 | +19.38% | 5 | Jul 31, 2025 | |
| SLNO Soleno Therapeutics | Maintains: Outperform | $105 → $121 | $52.93 | +128.60% | 5 | Jul 11, 2025 | |
| DYN Dyne Therapeutics | Maintains: Outperform | $46 → $32 | $18.37 | +74.20% | 2 | Jun 18, 2025 | |
| BIIB Biogen | Maintains: Outperform | $300 → $255 | $199.36 | +27.91% | 17 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $652 → $587 | $723.41 | -18.86% | 15 | Apr 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $95 → $100 | $134.94 | -25.89% | 3 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $30 | $11.84 | +153.38% | 1 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $26 → $20 | $14.53 | +37.65% | 6 | Nov 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $25 | $23.51 | +6.34% | 1 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Underperform | $215 | $336.29 | -36.07% | 4 | Sep 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $28 | $5.70 | +391.23% | 1 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $34 → $39 | $10.24 | +280.86% | 3 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $280 → $325 | $448.29 | -27.50% | 14 | May 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $10 | $28.65 | -65.10% | 2 | Aug 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $270 | $0.62 | +43,336.29% | 1 | May 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $18 → $6 | $4.15 | +44.58% | 1 | Feb 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $600 → $300 | $0.55 | +54,405.81% | 3 | May 7, 2018 |
Mirum Pharmaceuticals
May 7, 2026
Maintains: Outperform
Price Target: $112 → $129
Current: $106.88
Upside: +20.70%
Alto Neuroscience
Apr 2, 2026
Maintains: Outperform
Price Target: $41 → $38
Current: $24.63
Upside: +54.28%
Xenon Pharmaceuticals
Mar 9, 2026
Maintains: Outperform
Price Target: $63 → $97
Current: $55.00
Upside: +76.36%
Sarepta Therapeutics
Nov 4, 2025
Maintains: Neutral
Price Target: $21 → $15
Current: $19.13
Upside: -21.59%
Crinetics Pharmaceuticals
Sep 26, 2025
Maintains: Outperform
Price Target: $58 → $62
Current: $36.91
Upside: +67.98%
Biohaven
Aug 12, 2025
Maintains: Outperform
Price Target: $57 → $52
Current: $9.20
Upside: +465.22%
Neurocrine Biosciences
Jul 31, 2025
Maintains: Outperform
Price Target: $180 → $186
Current: $155.80
Upside: +19.38%
Soleno Therapeutics
Jul 11, 2025
Maintains: Outperform
Price Target: $105 → $121
Current: $52.93
Upside: +128.60%
Dyne Therapeutics
Jun 18, 2025
Maintains: Outperform
Price Target: $46 → $32
Current: $18.37
Upside: +74.20%
Biogen
May 2, 2025
Maintains: Outperform
Price Target: $300 → $255
Current: $199.36
Upside: +27.91%
Apr 30, 2025
Maintains: Neutral
Price Target: $652 → $587
Current: $723.41
Upside: -18.86%
Feb 12, 2025
Maintains: Neutral
Price Target: $95 → $100
Current: $134.94
Upside: -25.89%
Dec 13, 2024
Initiates: Outperform
Price Target: $30
Current: $11.84
Upside: +153.38%
Nov 26, 2024
Maintains: Outperform
Price Target: $26 → $20
Current: $14.53
Upside: +37.65%
Oct 31, 2024
Initiates: Outperform
Price Target: $25
Current: $23.51
Upside: +6.34%
Sep 25, 2024
Reiterates: Underperform
Price Target: $215
Current: $336.29
Upside: -36.07%
Jun 13, 2024
Initiates: Outperform
Price Target: $28
Current: $5.70
Upside: +391.23%
Mar 6, 2024
Maintains: Outperform
Price Target: $34 → $39
Current: $10.24
Upside: +280.86%
May 2, 2023
Maintains: Neutral
Price Target: $280 → $325
Current: $448.29
Upside: -27.50%
Aug 3, 2021
Downgrades: Neutral
Price Target: $10
Current: $28.65
Upside: -65.10%
May 20, 2021
Initiates: Outperform
Price Target: $270
Current: $0.62
Upside: +43,336.29%
Feb 26, 2021
Downgrades: Neutral
Price Target: $18 → $6
Current: $4.15
Upside: +44.58%
May 7, 2018
Maintains: Outperform
Price Target: $600 → $300
Current: $0.55
Upside: +54,405.81%